Amyopathic dermatomyositis with lung involvement responsive to mycophenolate mofetil

Immunopharmacol Immunotoxicol. 2013 Dec;35(6):687-92. doi: 10.3109/08923973.2013.833624. Epub 2013 Sep 5.


Amyopathic dermatomyositis (ADM) causes a severe pulmonary disease in 50% of patients and no validated therapeutic option is available. Mycophenolate mofetil permitted to control interstitial lung disease and pneumomediastinum in a patient with ADM. This drug has recently been used to treat interstitial lung disease in ADM, but its effectiveness has not been previously reported in case of pneumomediastinum. Patients with ADM need an accurate pulmonary surveillance and in case of pulmonary complications mycophenolate mofetil could be a new therapeutic option.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Dermatomyositis / drug therapy*
  • Dermatomyositis / pathology
  • Enzyme Inhibitors / administration & dosage*
  • Humans
  • Lung Diseases, Interstitial / drug therapy*
  • Lung Diseases, Interstitial / pathology
  • Male
  • Mediastinal Emphysema / drug therapy*
  • Mediastinal Emphysema / pathology
  • Mycophenolic Acid / administration & dosage
  • Mycophenolic Acid / analogs & derivatives*


  • Enzyme Inhibitors
  • Mycophenolic Acid

Supplementary concepts

  • Amyopathic dermatomyositis